Consensus recommendations for the assessment and treatment of rheumatoid arthritis

Journal of Rheumatology

Volumn 28, Issue 6, 2001, Pages 1423-1430

  Wolfe, F ^a   Cush, J J ^a   O'Dell, J R ^a   Kavanaugh, A ^a   Kremer, J M ^a   Lane, N E ^a   Moreland, L W ^a   Paulus, H E ^a   Pincus, T ^a   Russell, A S ^a   Wilskie, K R ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

ALGORITHM; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE ACTIVITY; DRUG EFFICACY; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS;

EID: 0034992675     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (142)

1. A survey of United States rheumatologists concerning effectiveness of disease-modifying antirheumatic drugs and prednisone in the treatment of rheumatoid arthritis
2. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: Follow-up after a mean of 13.3 years
3. Longterm treatment of destructive rheumatoid arthritis with methotrexate
4. The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis
5. Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis
6. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy
7. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
8. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis
9. Soluble tumor necrosis factor receptor (p75) fusion protein (Enbrel) as a therapy for rheumatoid arthritis
10. Biologic agents and immunotherapy in rheumatoid arthritis: Progress and perspective
11. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
12. Review: Biologic agents for treating rheumatoid arthritis - Concepts and progress
13. Predicting the short term direct medical costs incurred by patients with rheumatoid arthritis
14. Safety, cost and effectiveness issues with disease modifying antirheumatic drugs in rheumatoid arthritis
15. Report of the OMERACT task force on economic evaluation
16. Roundtable II: Cost concerns for rheumatoid arthritis treatment
17. The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies
18. Order out of chaos - The primary mission of the pyramid
19. Therapy of rheumatoid arthritis. A pyramidal plan
20. Back to the future: The pyramids of rheumatoid arthritis
21. Remodeling the pyramid - A concept whose time has not yet come
22. The mortality of rheumatoid arthritis
23. Remission in rheumatoid arthritis
24. The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the disease
25. Everyday life with osteoarthritis or rheumatoid arthritis: Independent effects of disease and gender on daily pain, mood, and coping
26. Pain in the rheumatic diseases: Investigation of a key health status component
27. Long-term course and outcome of functional capacity in rheumatoid arthritis - The effect of disease activity and radiologic damage over time
28. How much disability in rheumatoid arthritis is explained by rheumatoid arthritis?
29. Percentile curve reference charts of physical function: Rheumatoid arthritis population
30. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years
31. What is the natural history of rheumatoid arthritis?
32. The incidence and severity of rheumatoid arthritis. Results from a county register in Oslo, Norway
33. Is it possible to predict the first year extent of pain and disability for patients with rheumatoid arthritis?
34. The assessment and prediction of functional disability i n RA
35. Clinical and health status measures over time - Prognosis and outcome assessment in rheumatoid arthritis
36. The natural history of rheumatoid arthritis
37. Evaluating severity and status in rheumatoid arthritis
38. Work disability in rheumatoid arthritis: Effects of disease, social, and work factors
39. Prognosis of functional capacity and work capacity in rheumatoid arthritis
40. The impact of rheumatoid arthritis on the homemaker
41. The work dynamics of the person with rheumatoid arthritis
42. Work disability among women with rheumatoid arthritis: The relative importance of disease, social, work, and family factors
43. Prediction of permanent work disability in a follow-up study of early rheumatoid arthritis: Results of a tree structured analysis using RECPAM
44. The longterm outcomes of rheumatoid arthritis: Work disability: A prospective 18 year study of 823 patients
45. Work disability in an inception cohort of patients with seropositive rheumatoid arthritis: A 20 year study
46. Work disability in rheumatoid arthritis 10 years after the diagnosis
47. The long-term outcomes of rheumatoid arthritis: A 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis
48. Radiographic damage in rheumatoid arthritis - Description by nonlinear models
49. Progression of radiographical changes in rheumatoid arthritis
50. Long-term outcome of treating rheumatoid arthritis: Results after 20 years
51. The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first 25 years of disease
52. Radiographic outcome of recent-onset rheumatoid arthritis: A 19-year study of radiographic progression
53. American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
54. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials
55. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
56. Disease activity in rheumatoid arthritis - Preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research
57. The Work of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT)
58. Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology
59. Current comment - Listening to the patient - A practical guide to self-report questionnaires in clinical care
60. Assessing the activity of rheumatoid arthritis
61. A patient-derive disease activity score can substitute for a physician-derived disease activity score in clinical research
62. Why not use OSRA? A comparison of overall status in rheumatoid arthritis (RA) with ACR core set and other indices of disease activity in RA
63. The prognosis of rheumatoid arthritis: Assessment of disease activity and disease severity in the clinic
64. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research: Psychometric properties and correlation with parameters of disease activity
65. A simple index to assess disease activity in rheumatoid arthritis
66. The rapid assessment of disease activity in rheumatology (RADAR) questionnaire - Validity and sensitivity to change of a patient self-report measure of joint count and clinical status
67. Validity of single variables and indices to measure disease activity in rheumatoid arthritis
68. Development of a Disease Activity Score based on judgment in clinical practice by rheumatologists
69. The relationship between serial measures of disease activity and outcome in rheumatoid arthritis
70. An assessment of the annual and long-term direct costs of rheumatoid arthritis - The impact of poor function and functional decline
71. Factors predicting outcome of rheumatoid arthritis: Results of a followup study
72. Effects of disease and corticosteroids on appendicular bone mass in postmenopausal women with rheumatoid arthritis: Comparison with axial measurements
73. Predictive factors in rheumatoid arthritis
74. Prediction of articular destruction in rheumatoid arthritis: Disease activity markers revisited
75. Radiographic damage in large joints in early rheumatoid arthritis: Relationship with radiographic damage in hands and feet, disease activity, and physical disability
76. Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis
77. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: A prospective study during the first three years of the disease
78. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients
79. Risk factors for hospitalization and surgery in patients with rheumatoid arthritis: Implications for capitated medical payment
80. Clinical and radiographic outcomes of rheumatoid arthritis patients not treated with disease-modifying drugs
81. Longterm mortality outcome in patients with rheumatoid arthritis: Early presenters continue to do well
82. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: Randomized comparison of combined stepdown prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumatoide Artritis
83. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies
84. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis
85. Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
86. Paucity of radiographic progression in rheumatoid arthritis treated with MTX as the first disease modifying antirheumatic drug
87. Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients - A meta-analysis
88. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
89. Methotrexate in rheumatoid arthritis: Effects on disease activity in a multicenter prospective study
90. Longterm prospective study of methotrexate in rheumatoid arthritis: Conclusion after 132 months of therapy
91. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months
92. Historical overview of the treatment of rheumatoid arthritis with an emphasis on methotrexate
93. Current treatment by United States and Canadian pediatric rheumatologists
94. Early aggressive DMARD therapy: The key to slowing disease progression in rheumatoid arthritis
95. Early referral, diagnosis, and treatment of rheumatoid arthritis: Evidence for changing medical practice
96. Radiologic progression in early rheumatoid arthritis treated with methotrexate
97. Combination DMARD therapy including corticosteroids in early rheumatoid arthritis
98. Treatment of early seropositive rheumatoid arthritis with minocycline - Four-year followup of a double-blind, placebo-controlled trial
99. Aggressive treatment of early rheumatoid arthritis to prevent joint damage
100. Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate
101. Combination therapy in rheumatoid arthritis
102. Use of combination therapy in the routine care of patients with rheumatoid arthritis: Physician and patient surveys
103. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial
104. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications
105. Combination DMARD treatment with parenteral gold and methotrexate
106. The role of current strategies in the future treatment of rheumatoid arthritis
107. Future trends in the treatment of rheumatoid arthritis: Cytokine targets
108. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
109. Inhibitors of tumor necrosis factor for rheumatoid arthritis
110. Data collection in the clinic
111. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: The importance of drug and surgery costs
112. Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: A critical review of the literature and proposed methodologic standards
113. The relative toxicity of nonsteroidal antiinflammatory drugs
114. Impact of specific therapy upon rheumatoid arthritis
115. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models
116. The effect of age on methotrexate efficacy and toxicity
117. Toleration, side-effects and efficacy of sulphasalazine in rheumatoid arthritis patients of different ages
118. Socio-economic consequences of rheumatoid arthritis in the first years of the disease
119. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: Results of a five year prospective study
120. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression
121. Early treatment of rheumatoid arthritis: Rationale, evidence, and implications
122. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A or methotrexate
123. Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs
124. Treatment of early rheumatoid arthritis: A review of current and future concepts and therapy
125. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: The HERA study
126. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials
127. The relative toxicity of disease-modifying antirheumatic drugs
128. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study
129. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A follow-up study
130. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate
131. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
132. Inhibitors of tumor necrosis factor for rheumatoid arthritis
133. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF-alpha treatment
134. The 'side effects' of rheumatoid arthritis: Joint destruction, disability and early mortality
135. Systemic glucocorticoid treatment in rheumatoid arthritis - A debate
136. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis
137. Benefits of low-dose corticosteroids in rheumatoid arthritis
138. Low-dose corticosteroid therapy in rheumatoid arthritis: Balancing the evidence
139. The effect of glucocorticoids on joint destruction in rheumatoid arthritis
140. Differences in the use of secondline agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists
141. Referral and diagnosis of common rheumatic diseases by primary care physicians
142. Reliability of the diagnosis of rheumatic conditions at the primary health care level